Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663855 · ClinicalTrials.gov registry record · Phase 2
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03663855 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT03663855, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the effect of escalating doses of cystine binding thiol drugs on the cystine capacity of the urine. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger dosages. Cystinuria is a rare genetic disease that can lead to significant morbidity in affected patients due to the recurrent nature of the disease. This study will follow the levels of urine cystine capacity in order to help guide treatment and to use lower than usually prescribed Tiopronin doses to decrease the potential side effects while maintaining therapeutic benefit. This will increase adherence with the medications by decreasing the burden of the large number of pills that need to be taken daily.
Interventions
- DRUG Tiopronin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663855
The ClinicalTrials.gov registry entry for NCT03663855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiopronin is the first listed.
NCT03663855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03663855 about?
NCT03663855 is a clinical study titled "Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria". The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the effect of escalating doses of cystine binding thiol d...
What is the current status of trial NCT03663855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-11-01. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03663855?
The interventions under investigation include: Tiopronin (DRUG).
Who is sponsoring clinical trial NCT03663855?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.